Matrix Metalloproteinases in the Neocortex and Spinal Cord of Amyotrophic Lateral Sclerosis Patients

Abstract: Matrix metalloproteinases (MMPs) were analyzed by immunohistochemistry and zymography in amyotrophic lateral sclerosis (ALS) and control brain and spinal cord specimens. Three major bands of enzyme activity (70, 100, and 130 kDa) were consistently observed and were subsequently identified as MMP‐2 (70 kDa; also known as EC 3.4.24.24 or gelatinase A) and MMP‐9 (100 and 130 kDa; also known as EC 3.4.24.35 or gelatinase B). Immunohistochemical studies established the presence of MMP‐2 in astrocytes and MMP‐9 in pyramidal neurons in the motor cortex and motor neurons in the spinal cord of ALS patients. Although a significant decrease in MMP‐2 activity was noticed in the ALS motor cortex, statistically significant increases in MMP‐9 (100‐kDa) activity were observed in ALS frontal and occipital cortices (BA10 and 17) and all three spinal cord regions when compared with control specimens. The highest MMP‐9 (100‐kDa) activities in ALS were found in the motor cortex and thoracic and lumbar cord specimens. The abnormally high amount of MMP‐9 and its possible release at the synapse may destroy the structural integrity of the surrounding matrix, thereby contributing to the pathogenesis of ALS.

[1]  P. Gottschall,et al.  Cytokines Regulate Gelatinase A and B (Matrix Metalloproteinase 2 and 9) Activity in Cultured Rat Astrocytes , 1995, Journal of neurochemistry.

[2]  Z. Tökés,et al.  The 84‐kDa Form of Human Matrix Metalloproteinase‐9 Degrades Substance P and Gelatin , 1995, Journal of neurochemistry.

[3]  S. Estus,et al.  Altered gene expression in neurons during programmed cell death: identification of c-jun as necessary for neuronal apoptosis , 1994, The Journal of cell biology.

[4]  L. Liotta,et al.  Injury-induced 92-kilodalton gelatinase and urokinase expression in rat brain. , 1994, Laboratory investigation; a journal of technical methods and pathology.

[5]  W. Stetler-Stevenson,et al.  Quantitative zymography: detection of picogram quantities of gelatinases. , 1994, Analytical biochemistry.

[6]  D. Brems,et al.  Secondary structure of amyloid beta peptide correlates with neurotoxic activity in vitro. , 1994, Molecular pharmacology.

[7]  L. Liotta,et al.  Induction of tissue‐type plasminogen activator and 72‐kDa type‐IV collagenase by ionizing radiation in rat astrocytes , 1994, International journal of cancer.

[8]  D. Richman,et al.  Neuromuscular transmission in amyotrophic lateral sclerosis , 1993, Muscle & nerve.

[9]  M. Pericak-Vance,et al.  Amyotrophic lateral sclerosis and structural defects in Cu,Zn superoxide dismutase. , 1993, Science.

[10]  D. Miles,et al.  Activity of type IV collagenases in benign and malignant breast disease. , 1993, British Journal of Cancer.

[11]  J. Haines,et al.  Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis , 1993, Nature.

[12]  A. Strongin,et al.  Interaction of 92-kDa type IV collagenase with the tissue inhibitor of metalloproteinases prevents dimerization, complex formation with interstitial collagenase, and activation of the proenzyme with stromelysin. , 1992, The Journal of biological chemistry.

[13]  C. Miller,et al.  Characterization of Neutral Proteinases from Alzheimer‐Affected and Control Brain Specimens: Identification of Calcium‐Dependent Metalloproteinases from the Hippocampus , 1992, Journal of neurochemistry.

[14]  H. Herzog,et al.  Frontal lobe function in amyotrophic lateral sclerosis: a neuropsychologic and positron emission tomography study , 1992, Acta neurologica Scandinavica.

[15]  Mb Alan J. McComas Dr.,et al.  The extent and time course of motoneuron involvement in amyotrophic lateral sclerosis. , 1991 .

[16]  U. Moll,et al.  Tumor promoter-stimulated Mr 92,000 gelatinase secreted by normal and malignant human cells: isolation and characterization of the enzyme from HT1080 tumor cells. , 1990, Cancer research.

[17]  Y. Okada,et al.  The precursor of a metalloendopeptidase from human rheumatoid synovial fibroblasts. Purification and mechanisms of activation by endopeptidases and 4-aminophenylmercuric acetate. , 1988, The Biochemical journal.

[18]  D. Selkoe,et al.  Immunochemical identification of the serine protease inhibitor α 1-antichymotrypsin in the brain amyloid deposits of Alzheimer's disease , 1988, Cell.

[19]  R. Rhodes,et al.  Immunohistochemical demonstration of proteinase inhibitor alpha‐1‐antichymotrypsin in normal human central nervous system , 1987, Journal of cellular biochemistry.

[20]  A. Eisen,et al.  Human skin fibroblast procollagenase: mechanisms of activation by organomercurials and trypsin. , 1983, Biochemistry.

[21]  M. Baggiolini,et al.  The latent collagenase and gelatinase of human polymorphonuclear neutrophil leucocytes. , 1980, The Biochemical journal.

[22]  R. Nicoll,et al.  Substance P as a transmitter candidate. , 1980, Annual review of neuroscience.

[23]  T. Hökfelt,et al.  Distribution of substance P-like immunoreactivity in the central nervous system of the rat—I. Cell bodies and nerve terminals , 1978, Neuroscience.

[24]  J. Woessner.  The family of matrix metalloproteinases. , 1994, Annals of the New York Academy of Sciences.

[25]  M. Ball,et al.  Proteolysis of A beta peptide from Alzheimer disease brain by gelatinase A. , 1994, Biochemical and biophysical research communications.

[26]  L. Liotta,et al.  Elevated levels of M(r) 92,000 type IV collagenase in human brain tumors. , 1993, Cancer research.

[27]  W. Baricos,et al.  Degradation of human glomerular basement membrane by stimulated neutrophils. Activation of a metalloproteinase(s) by reactive oxygen metabolites. , 1987, The Journal of clinical investigation.

[28]  G. Buettner.  Cu-Zn Superoxide Dismutase , 1982 .

[29]  J. Hughes.  Pathology of amyotrophic lateral sclerosis. , 1982, Advances in neurology.